产品详情
In vitro (25°C) | DMSO | 92 mg/mL (183.44 mM) | |
Water | Insoluble | ||
Ethanol | Insoluble | ||
In vivo | 2% DMSO+30% PEG 300+5% Tween 80+ddH2O | 4 mg/mL | |
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
0.1 mM | 19.94 mL | 99.7 mL | 199.4 mL |
0.5 mM | 3.99 mL | 19.94 mL | 39.88 mL |
1 mM | 1.99 mL | 9.97 mL | 19.94 mL |
5 mM | 0.4 mL | 1.99 mL | 3.99 mL |
*The above data is based on the productmolecular weight 501.5 . Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
目录号 | A10996 |
---|---|
作用机制 | Inhibitor (抑制剂) |
M. Wt | 501.5 |
Formula | C28H24FN3O5 |
Purity | >99% |
Storage | Store lyophilized at -20ºC, keep desiccated. |
CAS No. | 849217-68-1 |
Synonyms | BMS-907351 |
SMILES | COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F |
产品资料
产品标签
Product Questions
Product Questions
Tivozanib (AV-951)
Tivozanib (AV-951)是一种口服VEGF受体酪氨酸激酶抑制剂,旨在抑制所有三种VEGF受体。
E7080 (Lenvatinib)
E7080 (Lenvatinib)是一种多激酶抑制剂,可同时抑制VEGFR2和VEGFR3激酶。
XL647 (Tesevatinib)
XL647 (Tesevatinib)是一种口服生物可利用的小分子RTK抑制剂,可结合并抑制在肿瘤细胞增殖和肿瘤血管形成中…
ZM 306416
ZM 306416 hydrochloride是一种VEGF受体酪氨酸激酶抑制剂,可抑制KDR(IC50 = 100 nM)和Flt(IC50 = 2 uM)酪氨酸激酶…
NVP-BAW2881
NVP-BAW2881是有效的选择性VEGFR抑制剂(血管内皮生长因子受体酪氨酸激酶抑制剂),IC50 为值9 nM,具有抑制…
Cediranib (AZD2171)
Cediranib (AZD2171)是一种高效的VEGFR(KDR)抑制剂,此外对c-Kit和PDGFRβ也具有相似的抑制活性,对VEGFR的选择性比P…